Pacific Biosciences of California, Inc.

XNASHealth care

Last traded price · USD

$2.51

−1.66%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:06 IST · A quote does not mean the product is available to trade on your account.

Day's open: $2.24
Previous close: $2.55
Volume: 1.2M
Day's high: $2.51
Day's low: $2.23

In brief

Pacific Biosciences of California, Inc. is a health care company listed on Nasdaq, valued at about $779M.
Its shares closed at $2.55 on 4 Nov 2026, up 27.5% over the past year.
From India you can buy PACB in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Pacific Biosciences of California, Inc. (PACB) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole PACB share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade PACB options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, behind its sector fund XLV over 1 year
1 month: −5.6% (SPY −1.6%, XLV +13.5%). 3 months: +96.2% (SPY −0.4%, XLV +15.5%). 1 year: +27.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PACB, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $2.55 was 34.6% above its 50-day average ($1.89) and 58.2% above its 200-day average ($1.61). It has closed above the 200-day for 30 sessions, since 24 Sep 2026. The 50-day average crossed above the 200-day on 16 Oct 2026, 13 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 15.1% of shares outstanding
46.9M shares were sold short at the 15 Oct 2026 settlement, 15.1% of the 310.8M shares outstanding; covering them would take 2.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
63% of the way up its 52-week range
Closed at $2.55 on 4 Nov 2026: 25.8% below the 52-week high of $3.44 (6 Oct 2026) and 138.3% above the low of $1.07 (12 Aug 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−5.6%

6 months+49.1%

1 year+27.5%

5 years−91.5%

Newswire

About

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

Website

Notable moves

September 30, 2026
+29.51%
July 16, 2024
+34.26%
April 16, 2024
−50.62%

Pacific Biosciences of California, Inc.

XNASHealth care

Last traded price · USD

$2.51

−1.66%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:06 IST · A quote does not mean the product is available to trade on your account.

Day's open: $2.24
Previous close: $2.55
Volume: 1.2M
Day's high: $2.51
Day's low: $2.23

In brief

Pacific Biosciences of California, Inc. is a health care company listed on Nasdaq, valued at about $779M.
Its shares closed at $2.55 on 4 Nov 2026, up 27.5% over the past year.
From India you can buy PACB in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Pacific Biosciences of California, Inc. (PACB) shares from India?

Do I need the price of a whole PACB share to invest?

How much can I invest in US stocks in a year?

Can I trade PACB options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, behind its sector fund XLV over 1 year
1 month: −5.6% (SPY −1.6%, XLV +13.5%). 3 months: +96.2% (SPY −0.4%, XLV +15.5%). 1 year: +27.5% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PACB, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $2.55 was 34.6% above its 50-day average ($1.89) and 58.2% above its 200-day average ($1.61). It has closed above the 200-day for 30 sessions, since 24 Sep 2026. The 50-day average crossed above the 200-day on 16 Oct 2026, 13 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 15.1% of shares outstanding
46.9M shares were sold short at the 15 Oct 2026 settlement, 15.1% of the 310.8M shares outstanding; covering them would take 2.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
63% of the way up its 52-week range
Closed at $2.55 on 4 Nov 2026: 25.8% below the 52-week high of $3.44 (6 Oct 2026) and 138.3% above the low of $1.07 (12 Aug 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−5.6%

6 months+49.1%

1 year+27.5%

5 years−91.5%

Newswire

About

Website

Notable moves

September 30, 2026
+29.51%
July 16, 2024
+34.26%
April 16, 2024
−50.62%

Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc. in brief

Ahead of SPY, behind its sector fund XLV over 1 year

Above its 50- and 200-day averages

Short interest at 15.1% of shares outstanding

63% of the way up its 52-week range

Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc. in brief

Ahead of SPY, behind its sector fund XLV over 1 year

Above its 50- and 200-day averages

Short interest at 15.1% of shares outstanding

63% of the way up its 52-week range